Your browser doesn't support javascript.
loading
Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance
Brandi Freeman; Sandra Lester; Lisa Mills; Mohammad Ata Ur Rasheed; Stefany Moye; Olubukola Abiona; Geoffrey Hutchinson; Maria Morales-Betoulle; Inna Krapinunaya; Ardith Gibbons; Cheng-Feng Chiang; Deborah Cannon; John Klena; Jeffrey A. Johnson; Sherry Michelle Owen; Barney S. Graham; Kizzmekia S. Corbett; Natalie J. Thornburg.
Affiliation
  • Brandi Freeman; Centers for Disease Control and Prevention
  • Sandra Lester; Synergy America Inc.
  • Lisa Mills; Eagle Global Scientific
  • Mohammad Ata Ur Rasheed; Synergy America Inc.
  • Stefany Moye; Eagle Global Scientific
  • Olubukola Abiona; National Institutes of Health
  • Geoffrey Hutchinson; National Institutes of Health
  • Maria Morales-Betoulle; Centers for Disease Control and Prevention
  • Inna Krapinunaya; Centers for Disease Control and Prevention
  • Ardith Gibbons; Centers for Disease Control and Prevention
  • Cheng-Feng Chiang; Centers for Disease Control and Prevention
  • Deborah Cannon; Centers for Disease Control and Prevention
  • John Klena; Centers for Disease Control and Prevention
  • Jeffrey A. Johnson; Centers for Disease Control and Prevention
  • Sherry Michelle Owen; Centers for Disease Control and Prevention
  • Barney S. Graham; National Institute of Health
  • Kizzmekia S. Corbett; National Institutes of Health
  • Natalie J. Thornburg; Centers for Disease Control and Prevention
Preprint in English | bioRxiv | ID: ppbiorxiv-057323
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed to have had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population.
License
cc0
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Observational study / Prognostic study / Rct Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Observational study / Prognostic study / Rct Language: English Year: 2020 Document type: Preprint
...